24
Jun
2025

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.

Exhibitor at CPHI & PMEC China 2025 stand E2B12b, Pharma Ingredients
About Us

We are a leading biopharmaceutical company firstly developed the following products in China: rhG-CSF (filgrastim), Liraglutide(recombinant)，Enoxaparin sodium, Fulvestrant, Interleukin-11, Palonosetron Hydrochloride, rhBMP-2 , Fosaprepitant dimeglumine. Our product pipeline include: Semaglutide (recombinant), Semaglutide intermediate (Totally 29 amino acids), Recombinant Hyaluronidase, Pegfilgrastim, Dulaglutide,  Avatrombopag maleate, Daratumumab, Romosozumab, amylin analog, CD47-SIPR.


Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • CN
  • 2015
    On CPHI since
  • 5
    Certificates
  • 1000 - 4999
    Employees
Company types
Manufacturer/Innovator
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI & PMEC China 2025
  • 24 Jun 2025 - 26 Jun 2025
  • Shanghai New International Expo Center
  • Visit us at stand E2B12b, Pharma Ingredients

Products Featured at CPHI & PMEC China 2025

  • Semaglutide

    Product Semaglutide

    Diabetes and Obesity
  • Filgrastim

    Product Filgrastim

    Filgrastim, Neupogen, G-CSF, Indicated to neutropenia, Formulated bulk liquid, l  Injection (ampoule/PFS/vial) 75µg/unit, 150µg/unit, 300µg/unit, 450µg/unit

  • Fosaprepitant dimeglumine

    Product Fosaprepitant dimeglumine

    cancerbrhrbrEmend, CAS number: 265121-04-8
  • Dulaglutide

    Product Dulaglutide

    diabetes (recombinant route), API
  • Fulvestrant

    Product Fulvestrant

    an anti-cancer drug, Bulk and injection (PFS): 250mg in 5ml